Scienture Holdings, Inc. SCNX
3.45 USD +0.22 (+6.81%)
At closeNov 3, 2026, 4:02 PM EST
3.45 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
3.13 Day range 3.45
2.64 52-week range 27.75
- YTD
- -72.94%
- 1 year
- -80.54%
- Market cap
- 5.67M
- Revenue (ttm)
- -351.61K
- EPS (ttm)
- -52.75
- Shares out
- 8.73M
- YTD return
- -72.94%
- 1-year return
- -80.54%
- Volume
- 12.68K
- Avg volume
- 193.38K
- Open
- 3.20
- Previous close
- 3.23
- Day's range
- 3.13 – 3.45
- 52-week range
- 2.64 – 27.75
2Y -199.47 (-98.32%)
Key statistics
- Enterprise value
- 67.40M
- PEG ratio
- 0.00
- Price / sales
- -187.96
- Price / book
- 0.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -83.50%
- Free cash flow
- 0
- Total cash
- 579.10K
- Total debt
- 2.76M
- Return on equity
- 0.00%
- Short % of float
- 0.07%
- 50-day average
- 7.66
- 200-day average
- 9.36
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SCNX Revenue — quarterly 343.64K
SCNX Net income — quarterly -2.82M
SCNX EPS — quarterly -1.75
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics, and independent pharmacies. Scienture Holdings, Inc. is headquartered in Tampa, Florida.
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Country
- United States
- Website
- scienture.com
News
12 Health Care Stocks Moving In Thursday's After-Market Session 
Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript 
Maxim Group Maintains Buy on Scienture Holdings, Adjusts Price Target To $6 (reverse stock split 1:25) 
Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027 
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027 
12 Health Care Stocks Moving In Monday's After-Market Session 
SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M 
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth 
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability 
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Your note
Sign in to keep a note on SCNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AJJARAPU SURENDRA K | Chief Executive Officer | Stock Award(Grant) | Jan 4, 2024 | 0 |
| NEWELL A. JEFFREY | Director | Stock Award(Grant) | Dec 29, 2022 | 79,062 |
| PATEL PRASHANT | Chief Financial Officer | Stock Award(Grant) | Jan 4, 2024 | 0 |
| PETERSON MICHAEL L | Director | Stock Award(Grant) | Jan 12, 2023 | 118,940 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.24% | 20,500 | 155.19K | Sep 29, 2024 |
| Vanguard Group Inc | 0.17% | 14,548 | 110.13K | Sep 29, 2024 |
| UBS Group AG | 0.05% | 3,876 | 29.34K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.01% | 664 | 5.03K | Sep 29, 2024 |
| Blue Trust, Inc. | 0.00% | 357 | 2.70K | Sep 29, 2024 |
| Wells Fargo & Company | 0.00% | 9 | 68 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.17% | 14,548 | 110.13K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.04% | 3,529 | 26.71K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 2,004 | 15.17K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 945 | 7.15K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,027 | 7.77K | Oct 30, 2024 |